Mace

(redirected from Major Adverse Cardiovascular Events)
Also found in: Dictionary, Thesaurus, Financial, Encyclopedia.

Mace

 [mās]
trademark for an aerosol mixture of CS, a common tear gas.

Mace

, MACE (mās),
Acronym for methylchloroform 2-chloracetophenone (the prototypical lacrimator) in a light petroleum dispersant and a pressurized propellant.
An acronym for objective measures of acute and/or adverse cardiovascular events (e.g., acute myocardial infarction, ischaemic stroke, coronary arterial occlusion, death) which are used to assess the effects of various interventions (e.g., rotablation, angioplasty, stenting) or therapeutics (e.g., antiarrhythmics, statins, ACE inhibitors) on outcomes, in the context of a clinical trial.

Mace

A tear gas made from the lacrimatory agent chloracetophenone combined with a dispersant and an aerosol propellant.
References in periodicals archive ?
A low circulating active clopidogrel metabolite causes a diminished platelet response to treatment leading to higher rates of major adverse cardiovascular events [4, 9].
Finally, many patients present with a major adverse cardiovascular event with no previous history of cardiovascular disease and lipid levels within the normal ranges recommended by the National Cholesterol Education Program.
It has already been approved by the Food and Drug Administration to lower blood glucose in patients with Type 2 diabetes and to reduce the risk of major adverse cardiovascular events in patients with Type 2 diabetes and existing heart disease.
- Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxiga (dapagliflozin) reduced the relative risk of major adverse cardiovascular events by 16% compared to placebo (15.2% vs 17.8%; HR 0.84, [95% CI 0.72-0.99]) in patients with type 2 diabetes who had a prior heart attack (myocardial infarction), British-Swedish drugmaker AstraZeneca said.
Results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA reduced the relative risk of major adverse cardiovascular events by 16% compared to placebo in patients with type 2 diabetes who had a prior heart attack.
CAMELLIA-TIMI 61 met its primary safety objective, finding that long-term treatment with BELVIQ did not increase the incidence of major adverse cardiovascular events (MACE) in overweight and obese patients at high risk for a CV event.
The relative risk of major adverse cardiovascular events was highest in individuals with low or moderate baseline risk, while the highest absolute risk was seen for individuals with high baseline risk.
In 4 years on secukinumab, there were no cases of tuberculosis, neutropenia, major adverse cardiovascular events, or Crohn's disease.
Major adverse cardiovascular events were compared between patients of occluded and non- occluded coronary aetery.
The rate of major adverse cardiovascular events was higher among patients treated with varenicline than those on placebo in a meta-analysis, but the difference was not statistically significant, according to the latest Food and Drug Administration statement on the cardiovascular safety of the smoking cessation drug.
Compared with noncarriers, the risk for developing major adverse cardiovascular events is 1.55 (95% CI, 1.11-2.17) for heterozygotes (intermediate metabolizers) and 1.76 (95% CI, 1.24-2.50) for homozygotes (poor metabolizers).
Efficacy observations related to structural and functional end points including major adverse cardiovascular events (MACE), New York Heart Association (NYHA) functional classification, 6-minute walk distance, and septal wall thickening, were consistent with improved function of impaired myocardium.

Full browser ?